Reviewer's report

Title: A Multicenter Phase II Study of Everolimus in Patients with Progressive Unresectable Adenoid Cystic Carcinoma

Version: 2 Date: 1 September 2014

Reviewer: Filippo FDB de Braud

Reviewer's report:

PFS at 4 mos it is a very unusual end point even for thisi disease in a phase II study we wish to have prove of activity

PET FdG is not a proper way to evaluate ACC

There are at least 3 experiences showing Recist responses with target agents in ACC

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I had reimbursment and fees and founding from Novartis